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license (http://creativetheir plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia.
Methods: Wemeasured 188 plasma metabolites in participants who underwent a detailed neuropsy-
chological assessment and classified as normal (n5 153), MCI (n5 145), or dementia (n5 143) by
expert adjudication.
Results: Among 10 phospholipids recently implicated as altered in dementia, higher concentra-
tion of PC aa C36:6 was significantly associated with decreased prevalence of dementia
(odds ratio 5 0.71, 95% confidence interval 5 0.50–1.00 per 12SD increase). Adding these
phospholipids to a model including multiple predictors of dementia led to only minimal improve-
ment in detection (C statistic changed from 0.702 to 0.71).
Discussion: Some phospholipids and metabolites were altered in MCI and dementia but cross-
sectional association was relatively weak and did not improve detection ofMCI and dementia beyond
information provided by clinical variables.
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There is a growing interest in discovery of plasma bio-
markers for prediction and diagnosis of mild cognitive
impairment (MCI) and dementia, in particular MCI and de-
mentia due to Alzheimer’s disease (AD). Currently, amnes-uthor. Tel.: 11-612-626-0299; Fax: 11-612-625-
nnili@umn.edu
16/j.dadm.2016.02.008
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).ticMCI (aMCI) and AD-type dementia, similar to otherMCI
and dementia, are generally diagnosed based on a full assess-
ment of cognitive function, a neurological examination, and
clinical examination of history in cognitive and behavioral
changes. Positron emission tomography neuroimaging and
cerebrospinal fluid proteins are important but invasive and
expensive tools for verifying the diagnosis. Owing to the
complexity of AD pathology, mounting evidence shows
that no single biomarker can yield enough sensitivity and
specificity, and multiple biomarkers may be necessary toimer’s Association. This is an open access article under the CC BY-NC-ND
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are less invasive and may be used as a first-step screen of
AD. Moreover, the less invasive nature of plasma bio-
markers makes them potentially more suitable for moni-
toring disease progression and treatment response to
potential therapies in AD.
Previous work has documented altered concentrations of
phospholipids in brains of aging, cognitive function decline,
MCI, and dementia [1–3]. Furthermore, plasma
phospholipids were associated with cognitive function
during middle adulthood [4], the risk of decline in verbal
fluency [5], and a significant reduction in risk of developing
all-cause dementia [6]. Recently, Mapstone et al. reported a
panel of plasma phospholipids that identified cognitive
normal adults who would progress to either aMCI or AD
within 2–3 years from those who remained cognitively
normal (the area under curve [AUC] of the receiver-
operating characteristic [ROC] analysis was 0.96 [95% con-
fidence interval, 0.93–0.99]) [7]. In addition to the index
finding, these 10 phospholipids also discriminated aMCI/
AD from cognitive normal with an AUC of 0.827 in the
initial discovery (n5 88) and an AUC of 0.77 in an indepen-
dent validation (n 5 41) [7]. Subsequently, three publica-
tions suggested that plasma phospholipids and metabolites
might aid in the clinical diagnosis of MCI and dementia
[8–10]. With the general aim of validating the biomarkers
identified by Mapstone et al. for detection of MCI and
dementia and not for prediction, we examined the cross-
sectional association of concentrations of selected phospho-
lipids with the prevalence of MCI or dementia in a subset of
participants in the Atherosclerosis Risk in Communities
(ARIC) Neurocognitive Study (ARIC-NCS).2. Methods
2.1. ARIC-NCS study
The ARIC study is a prospective cohort study investi-
gating the etiology of atherosclerotic diseases in a middle-
aged, predominantly biracial population. A detailed study
design description was published [11].2.2. Standard protocol approvals and patient consents
The ARIC Study and ARIC-NSC protocols were
approved by the institutional review board of each partici-
pating center, and informed consent was obtained from par-
ticipants at each study visit.2.3. Measures of cognitive performance
As part of the ARIC-NCS, all participants underwent a
physical examination, collection of blood samples, and a
detailed neurocognitive assessment in 2011–2013. Measures
of cognitive function in ARIC-NCS have been described in
detail [12].Participants who had a low mini mental state examina-
tion (MMSE) score (,21 in whites, ,19 in African Amer-
icans), those with low scores in the cognitive testing (,1.5
standard deviations below norms applicable to our specific
populations in any single domain) and cognitive decline (as
evidenced by decrease in cognitive tests from previous ex-
aminations), together with a random subset of participants
without evidence of cognitive impairment, underwent a
neurological examination, and were administered the Clin-
ical Dementia Rating (CDR) scale, both the informant and
the subject interviews. A subset of participants without
contraindications underwent a brain magnetic resonance
imaging (MRI) study, as described elsewhere [13]. Briefly,
MRI scans were provided in each site on 3-Tesla scanners
using a common set of sequences including 3-D volumetric
magnetization and fluid-attenuated inversion recovery se-
quences.2.4. Diagnosis and adjudication of MCI and dementia
Two study reviewers, a neurologist and a neuropsycholo-
gist, reviewed independently data on each participant and
rendered a diagnosis of normal cognition, MCI, or dementia.
After the established of the syndromic diagnosis, an etio-
logic diagnosis was made for participants with MCI or de-
mentia diagnoses. Discordant cases were assigned to a
third independent reviewer [13].
Functional assessment questionnaire (FAQ) and CDR
were used. Although the FAQ score was not administrated
as a distinct scale, the items for the FAQ were embedded
with the CDR. A diagnosis of MCI was assigned in per-
sons without dementia who met the three criteria below:
(1) FAQ 5 or CDR sum of boxes 3, (2) at least one
neuropsychological cognitive domain Z score ,21.5 or
clock time perception reading failure, and (3) documented
decline in ARIC serial cognitive test battery of these tests:
delayed word recall (DWR), digit symbol substitution
(DSS), and word fluency (WF) (i.e., falling at or below
the worst 20th percentile of change on .1 test or below
the worst 10th percentile on at least 1 test; with change
calculated as current score minus the highest prior score).
Dementia diagnosis was made either (1) by a low MMSE
score (,21 in whites, ,19 in African Americans), even in
the absence of more complete cognitive testing, if, in the
judgment of the Classification Committee, any prior
DWR, DSS, and WF scores were not indicative of demen-
tia, or (2) by meeting all three of the following criteria:
FAQ  5 or CDR sum of boxes .3, at least two neuropsy-
chiatric cognitive domain scores , 21.5, and documented
decline in ARIC serial cognitive test battery (as defined
above).
Etiologic diagnoses were recorded as primary or sec-
ondary. Primary diagnoses and all vascular diagnoses,
whether primary or secondary, were adjudicated. The
diagnosis of AD as an etiologic diagnosis of MCI or de-
mentia as a primary diagnosis was a clinical one and
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not of abrupt onset and included memory impairment, in
the absence of features of other specific diagnoses suffi-
cient to cause the cognitive impairment. Cerebrovascular
disease–related MCI and/or dementia was recorded if
there was (1) history of stroke temporally related to an
abrupt onset of the cognitive disorder, (2) bilateral or mul-
tiple infarcts or extensive white-matter hyperintensities on
imaging, or (3) physical examination evidence of a typical
stroke pattern. In this study, AD-type dementia includes
dementia with AD as the primary diagnosis with or
without a secondary diagnosis; all dementia cases that
are not AD-type dementia are considered as non-AD
type dementia.2.5. Sample collection, handling, and storage
The ARIC-NCS study collected fasting blood samples
from all participants using standard protocols. Fasting
EDTAwhole blood was collected and placed in ice bath until
further processing by centrifugation (i.e., 10 minutes at 3000
g in 4C). After the centrifugation, plasma supernatant was
aliquoted and stored in280C freezers until further shipping
on dry ice for long-term storage. The sample collection and
processing protocols are compatible with stability of plasma
lipoproteins [14] and phospholipids [15]. EDTA plasma
samples that were never thawed were used in this study for
targeted metabolomics analysis to minimize the effects of
freeze-thaw on plasma phospholipids and metabolites.2.6. Sample selection
The ARIC-NCS had 216 dementia, 934 MCI, and 1547
cognitive normal black and white participants. We sampled
approximately 73 cases from each MCI/race group and de-
mentia/group without regard to etiologic diagnoses. Then,
we sampled approximately 73 controls from each race group
by frequency matching on APOE genotype, age, sex, race,
education, and study center (in order) with the frequency dis-
tribution of controls matching that of the combined MCI and
dementia cases.2.7. Phospholipids measurement
Targeted metabolomics analysis of plasma samples was
performed using the Biocrates Absolute-IDQ P180 kits
(Biocrates; Life Science AG, Innsbruck, Austria). The
plasma samples were processed as per the manufacturer in-
structions and analyzed on a triple-quadrupole mass spec-
trometer (AB Sciex QTRAP 6500). As part of the quality
control, three concentrations of quality controls were
included in each kit to monitor imprecisions (% coefficient
variances [CVs]) of measuring these 188 metabolites.
Means, standard deviations (SDs), and CVs of all the 188
metabolites in seven kits (the number of kits needed for anal-
ysis of the 441 samples) were calculated, and imprecisions.80% of the metabolites were ,20% for all three concen-
trations of QCs (Supplementary Table 1). Data analysis
was performed using the MetIQ software (Biocrates).
2.8. Statistical analysis
Metabolite concentrations were log transformed and
modeled in standard deviation units when possible. Eleven
metabolites had some 0 values, to which we imputed the
lowest nonzero measurement for analysis. Overall, 28 me-
tabolites had .80% missing or below limit of detection
(LOD) or had a failure in model convergence and therefore
were excluded (Supplementary Table 2). Ten metabolites
with 50%–80% missing or below LOD values were catego-
rized into three groups: ,LOD, LOD to , median, and
median (Supplementary Table 2). The main analysis
focused on 9 of the 10 phospholipids identified in the previ-
ous publication by Mapstone et al. as predictors of conver-
sion from normal to cognitive impairment (the 10th
metabolite, C16:1-OH, had values below the LOD in all
measurements) [7]. In the primary analysis, a multinomial
logistic regression was used to assess the association of the
individual metabolites with the prevalence of MCI and de-
mentia (three-level dependent variable: normal, MCI, de-
mentia, n 5 441). The following variables were used for
adjustment: model 1: age, race, sex, and APOE genotype
and model 2: model 11 educational level, diabetes mellitus,
body mass index, drinking status, smoking status, sports in-
dex, systolic blood pressure, use of antihypertensivemedica-
tions, prevalent coronary heart disease, prevalent heart
failure, prevalent stroke, total cholesterol, high-density lipo-
protein cholesterol, and triglycerides at the ARIC-NCS.
These covariates were assessed at ARIC visit 5/NCS exam-
ination, the same time when the plasma samples were taken
from the 441 participants. Secondary separate analyses were
performed based on etiological groups of discriminating
aMCI and AD type dementia from normal (n 5 245). To
measure the ability of this panel of 10 phospholipids in the
classification of normal versus MCI and/or dementia, we
calculated the C statistic from binary logistic regression
models with dementia and/or MCI (vs. normal) as the
outcome with individual phospholipids modeled as a
12SD difference in the log-transformed phospholipid (un-
less noted). The C statistic is the proportion of pairs of sub-
jects with the outcome and subjects without the outcome in
which the subject who experienced the outcome had a higher
predicted probability of the outcome than the subject
without the outcome [16]. This statistic corresponds to the
AUC and is part of the standard output of PROC LOGISTIC
in SAS. Finally, linear regression analysis was performed to
estimate the association of concentrations of these nine
phospholipids with neuropsychological tests, modeled as z
scores. We used SAS, v 9.3 (SAS Inc., Cary, North Car-
olina), for the statistical analysis.
In an exploratory, hypothesis-generating analysis, we
repeated the analyses for the rest of 151 metabolites
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values lower than LOD and nine phospholipids from the
main analysis. This hypothesis-generating analysis adjusted
for the same variables used in model 2 above and was cor-
rected for multiple comparisons using a Bonferroni correc-
tion [17]. Therefore, only associations with a P value ,
.00033 (0.05/151 metabolites) were considered statistically
significant.3. Results
3.1. Baseline characteristics of individuals adjudicated as
normal, MCI, and dementia in ARIC
Table 1 presents the characteristics of the 441 ARIC-NCS
participants by dementia status in this study. Overall, indi-
viduals with dementia or MCI were older had a worse car-
diovascular risk profile and a higher prevalence of APOE ε4
allele.3.2. Associations of plasma phospholipids/metabolites
with MCI and/or dementia
Our main analysis focused on the 10 phospholipids
identified by Mapstone et al. [7]. Our hypothesis, based
on the findings of Mapstone et al., was that higher concen-
trations of these phospholipids would be associated with a
lower prevalence of MCI and/or dementia. Of these 10 me-
tabolites, concentrations of C16:1-OH in all participants
were lower than LOD (and considered unreliable). There-
fore, we excluded C16:1-OH from the analysis. Table 2 il-
lustrates results from multinomial logistic models
estimating the association of the remaining nine phospho-Table 1
Baseline characteristics by dementia status, ARIC-NCS study, 2011–2013
Characteristics Normal (n 5 153)
Age, years 77.6 (5.5)
African American, % 30.1
Female, % 60.1
Body mass index, kg/m2 28.6 (5.5)
Current drinker, % 44.4
Current smoker, % 3.9
Diabetes, % 30.1
High school graduate, % 45.8
HDL cholesterol, mg/dL 54.4 (14.2)
Hypertension medication, % 77.8
Prevalent CHD, % 9.8
Prevalent HF, % 1.3
Prevalent stroke, % 1.3
Systolic blood pressure, mmHg 131.1 (18.5)
Sports index 2.6 (0.8)
Total cholesterol, mg/dL 184.6 (39.8)
Triglycerides, mg/dL 120.9 (60.9)
APOE, % 44 1.3
24 or 34 26.1
Other 69.9
Data missing 2.6lipids with MCI and/or dementia. In unadjusted and mini-
mally adjusted models, higher concentrations of PC aa
C40:2 were significantly associated with a lower preva-
lence of MCI, whereas higher concentrations of PC aa
C36:6 were significantly associated with lower prevalence
of dementia, consistent with our hypothesis. After adjust-
ing for additional covariates in model 2, only the concen-
tration of PC aa C36:6 remained significantly associated
with dementia prevalence (odds ratio 5 0.71, 95% confi-
dence interval, 0.50–1.00).
Table 3 shows the ability (C-statistic) of these nine
phospholipids in classifying individuals as cognitive
normal versus MCI and/or dementia. Individual phos-
pholipids had C-statistics in the range of 0.522–0.580
in the unadjusted model. When combined, these phos-
pholipids had a slightly improved C-statistic of 0.602.
A model combining all the covariates but not concentra-
tions of phospholipids achieved a C-statistic of 0.702.
Adding to this model, individual phospholipids or all
nine phospholipids simultaneously led to minimal im-
provements in the C-statistic (range, 0.702–0.713).
Furthermore, we performed the analyses by focusing on
MCI and dementia with AD as the primary diagnosis
with or without a secondary diagnosis. None of these
nine phospholipids were significantly associated with
AD-type MCI or dementia (Supplementary Table 3).
Similarly, these phospholipids did not provide added
value in the detection of AD-type MCI or dementia prev-
alence (Supplementary Table 4).
In an exploratory, hypothesis-generating analysis, we
also analyzed the associations of the remaining 151
phospholipids/metabolites with MCI or dementia
(Supplementary Table 5). After adjusting for covariates (inMild cognitive impairment (n 5 145) Dementia (n 5 143)
76.5 (5.6) 79.7 (5.1)
17.2 37.8
47.6 55.2
29.7 (6.0) 27.9 (5.7)
44.8 31.5
4.8 4.2
46.2 39.2
45.5 32.2
49.1 (12.9) 52.5 (15.8)
79.3 80.4
20.0 25.9
2.1 7.0
5.5 10.5
130.7 (17.7) 134.3 (21.3)
2.6 (0.8) 2.3 (0.7)
174.6 (41.6) 183.9 (47.4)
125.6 (63.3) 127.3 (76.7)
2.1 9.1
33.8 37.8
62.1 48.3
2.1 4.9
Table 2
Odds ratio (OR) and 95% confidence interval (CI) of MCI and dementia by phospholipids (per 12SD difference in log-transformed metabolite, unless noted)
from a multinomial logistic regression model, ARIC-NCS study, 2011–2013
Phospholipids n
MCI vs. normal
OR (95% CI)*
Dementia vs. normal
OR (95% CI)*
MCI & dementia vs. normal
OR (95% CI)*
PC aa C36:6
Model 0 441 0.85 (0.67–1.07) 0.68 (0.54–0.87) 0.77 (0.62–0.93)
Model 1 441 0.81 (0.62–1.05) 0.69 (0.53–0.91) 0.76 (0.60–0.94)
Model 2 441 1.01 (0.73–1.40) 0.71 (0.50–1.00) 0.86 (0.64–1.13)
PC aa C38:0
Model 0 441 0.82 (0.65–1.04) 0.93 (0.74–1.17) 0.87 (0.72–1.06)
Model 1 441 0.95 (0.74–1.21) 0.88 (0.68–1.15) 0.92 (0.74–1.13)
Model 2 441 1.14 (0.85–1.53) 0.93 (0.68–1.27) 1.04 (0.81–1.34)
PC aa C38:6
Model 0 441 0.86 (0.68–1.08) 0.83 (0.66–1.04) 0.84 (0.69–1.03)
Model 1 441 0.90 (0.71–1.14) 0.80 (0.62–1.03) 0.85 (0.69–1.05)
Model 2 441 1.08 (0.81–1.43) 0.82 (0.60–1.11) 0.96 (0.75–1.24)
PC aa C40:1y
Model 0 441 0.76 (0.55–1.04) 0.95 (0.71–1.29) 0.85 (0.66–1.11)
Model 1 441 0.83 (0.59–1.15) 0.94 (0.68–1.30) 0.88 (0.67–1.16)
Model 2 441 0.94 (0.65–1.38) 0.96 (0.65–1.42) 0.94 (0.68–1.31)
PC aa C40:2
Model 0 441 0.73 (0.58–0.92) 1.01 (0.80–1.27) 0.86 (0.70–1.05)
Model 1 441 0.77 (0.60–0.98) 0.97 (0.76–1.24) 0.86 (0.70–1.06)
Model 2 441 0.85 (0.63–1.15) 1.04 (0.75–1.43) 0.92 (0.71–1.20)
PC aa C40:6
Model 0 441 0.85 (0.67–1.07) 0.83 (0.66–1.04) 0.84 (0.68–1.02)
Model 1 441 0.91 (0.71–1.16) 0.79 (0.61–1.02) 0.85 (0.69–1.06)
Model 2 441 1.04 (0.78–1.38) 0.75 (0.55–1.03) 0.91 (0.71–1.17)
PC ae C40:6
Model 0 441 0.81 (0.64–1.01) 0.89 (0.71–1.12) 0.85 (0.70–1.03)
Model 1 441 0.89 (0.70–1.14) 0.84 (0.65–1.08) 0.88 (0.71–1.08)
Model 2 441 1.12 (0.83–1.51) 0.86 (0.62–1.20) 1.02 (0.78–1.33)
Lyso PC a C18:2
Model 0 441 1.03 (0.82–1.29) 1.15 (0.91–1.45) 1.09 (0.89–1.32)
Model 1 441 0.93 (0.73–1.19) 1.14 (0.89–1.46) 1.04 (0.85–1.28)
Model 2 441 1.07 (0.81–1.41) 1.15 (0.85–1.54) 1.12 (0.88–1.43)
Propionyl-L-carnitine (C3)
Model 0 440 1.17 (0.93–1.47) 1.08 (0.86–1.36) 1.12 (0.92–1.37)
Model 1 440 1.14 (0.90–1.45) 1.13 (0.89–1.45) 1.13 (0.92–1.40)
Model 2 440 1.04 (0.78–1.38) 1.02 (0.76–1.37) 1.04 (0.82–1.34)
NOTE. Model 0: unadjusted logistic regression. Model 1: Logistic regression adjusted for age, race, sex, & APOE. Model 2: Model 1 with additional adjust-
ment for APOE, body mass index, diabetes mellitus, drinking status, educational level, HDL cholesterol, smoking status, sports index, systolic blood pressure,
total cholesterol, triglycerides, use of antihypertensive medications, and prevalent coronary heart disease, heart failure, or stroke at baseline.
*OR per 12SD change in the log(phospholipid).
yOR for phospholipid as a 3 group ordinal variable (below LOD, LOD2 , Median, Median).
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SM(OH) C22:1 was statistically significantly associated
with dementia (P value 5 .0003).3.3. Associations of plasma phospholipids/metabolites
with cognitive performance
We determined the associations of the nine phospho-
lipids with scores in the MMSE and 12 neuropsycholog-
ical tests across the 441 participants in this study (153
normal, 145 MCI, and 143 dementia; Table 4). After ad-
justing for multiple covariates, higher concentrations of
PC aa C40:6 and lyso PC aa C18:2 were associated
respectively with higher and lower values in the MMSEscore. Higher concentrations of PC aa C36:6, PC aa
C38:0, PC aa 38:6, PC aa C40:2, PC aa 40:6, and PC
ae 40:6 were significantly associated with better scores
in incidental learning, a neuropsychological test assess-
ing memory performance. Similarly, higher concentra-
tions of PC aa C36:6, PC aa 38:0, PC ae 40:6, and PC
aa C40:6 were associated with better scores in tests eval-
uating memory; higher concentrations of PC aa C38:0
and PC ae C40:6 were associated with better scores in
tests evaluating attention; higher concentrations of PC
aa C36:6 and C3 are associated with better scores in tests
evaluating executive function. Furthermore, we exam-
ined the association of two of these nine phospholipids
(PC aa C38:0 and PC ae C40: 6) with cognitive
Table 3
C-statistic from binary logistic regression models with dementia/MCI
(vs normal) as the outcome and individual phospholipids modeled as a 1-SD
difference in the log-transformed phospholipid unless noted*, ARIC-NCS
study, 2011–2013
Models
C statistic
Model 0 Model 2
Model (No Phospholipids) 0.702
Model 1 PC aa C36:6 0.580 0.704
Model 1 PC aa C38:0 0.534 0.703
Model 1 PC aa C38:6 0.544 0.702
Model 1 PC aa C40:1* 0.522 0.702
Model 1 PC aa C40:2 0.548 0.703
Model 1 PC aa C40:6 0.546 0.703
Model 1 PC ae C40:6 0.547 0.704
Model 1 Lyso PC a C18:2 0.522 0.704
Model 1 Propionyl-L-carnitine (C3) 0.532 0.701
Model 1 all 9 phospholipids 0.602 0.713
NOTE. Model 0: Unadjusted logistic regression. Model 2: model 1 with
additional adjustment for APOE, body mass index, diabetes mellitus, drink-
ing status, educational level, HDL cholesterol, smoking status, sports index,
systolic blood pressure, total cholesterol, triglycerides, use of antihyperten-
sive medications, and prevalent coronary heart disease, heart failure, or
stroke at baseline.
*The phospholipid is modeled as a three-group ordinal variable (below
LOD, .LOD2 ,Median, .Median).
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(Table 5). We found that overall their associations with
cognitive performance were stronger in cognitive normal
participants than in the whole study population (Table 5
vs. Table 4).4. Discussion
We performed targeted metabolomics of 188 metabo-
lites (i.e., 40 acylcarnitines, 21 amino acids, 21 biogenic
amines, 15 sphingolipids, 90 glycerophospholipids, and
hexose) on plasma samples from 153 cognitively normal,
145 MCI, and 143 dementia participants in the multi-
center ARIC-NCS study. We hypothesized that (a) lower
concentrations of the 10 phospholipids identified by
Mapstone et al. (PC aa C36:6, PC aa C38:0, PC aa
C38:6, PC aa C40:1, PC aa C40:2, PC aa C40:6, and
PC ae C40:6, lyso PC a C18:2, C3, and C16:1-OH) would
be associated with a higher prevalence of MCI and de-
mentia, and (b) that these phospholipids would help clas-
sify individuals as cognitively normal or impaired (MCI
and/or dementia). Our multinomial logistic regression an-
alyses adjusted for age, race, sex, APOE genotype, and
additional cardiovascular risk factors indicated that, of
the 10 phospholipids identified by Mapstone et al. only
PC aa C40:2 and PC aa C36:6 were associated with prev-
alence of MCI and dementia, respectively. Being a
hypothesis-driven analysis, we did not adjust for multiple
testing for these phospholipids. Similarly, Klavins et al.
[8] showed an association of lower concentrations ofPC aa C36: 6 with MCI and dementia. In our analysis,
the phospholipids identified by Mapstone et al. had
weaker associations individually and in aggregate and a
limited ability to differentiate those with dementia and/
or MCI from the cognitively normal. Overall, other vari-
ables, including sociodemographic and cardiovascular
risk factors, had better ability to detect MCI and demen-
tia than the phospholipids of interest, as evaluated with
C-statistics.
Higher concentrations of SM(OH) C22:1 were signif-
icantly associated with lower prevalence of dementia.
Furthermore, higher concentrations of three additional
sphingomyelins (SM C26:0, SM(OH) C22:2, SM(OH)
C24:1) were similarly associated with lower prevalence
of dementia, though these associations did not reach
the Bonferroni-corrected level of statistical significance.
Although dementia can have many etiologies, and AD is
one of the many etiologies that may be responsible [18],
our results are consistent with literature findings on the
link between AD and sphingomyelins [19,20].
Our study has several limitations. First, we used stored
plasma samples. It is well known that pre-analytical vari-
ables in sample collection and processing may affect con-
centrations of phospholipids and metabolites in plasma
[15,8]. Kalvins et al. specifically tested stability of
plasma phospholipids analyzed by the Biocrates p180
kits, which were the kits we used in this study and
found if blood samples were processed immediately
after collection and stored in 220C, there were no
statistically significant difference in the levels of plasma
phospholipids between when these samples were
analyzed on the same day of collection and when they
were analyzed after 2 years of storage [8]. ARIC-NCS
collected blood samples using standardized protocols,
which instruct immediate blood processing after collec-
tion and storage of plasma samples at 280C. In addition,
these samples used in this study had been in storage for up
to 3 years (in average ,2 years) before they were
analyzed. Furthermore, we used never-thawed plasma
specimens to prevent the effects of freeze-thaw on spec-
imen quality [15]. Therefore, the plasma specimens used
in our study were of high quality and considered to be
suitable for plasma phospholipids analysis. Second, we
did not correct for multiple testing of the phospholipids
in our primary analysis, because these phospholipids
have been previously identified [7]. However, we did cor-
rect for multiple testing when we performed the explor-
atory, hypothesis-generating analysis of the rest of 151
metabolites. Third, we used the cross-sectional design,
which did not allow the assessment of temporality.
Finally, we had relatively small sample size to investigate
the association of phospholipids with subtypes of demen-
tia and/or MCI subtypes (AD vs. no-AD). Also, our clin-
ical diagnoses of AD-type MCI and dementia lacked
sufficient additional biomarker data to be certain about
the AD etiology.
Table 4
The associations of selected phospholipids/metabolites with scores in the MMSE and 12 neuropsychological tests across the 441 participants in ARIC-NCS,
2011–2013
Neuropsychological tests
PC aa C36:6 PC aa C38:0 PC aa C38:6
n b* 95% CI
P
value n b* 95% CI
P
value n b* 95% CI
P
value
Mini-mental state examination 388 0.06 20.04 0.16 .22 388 0.04 20.06 0.13 .41 388 0.07 20.03 0.16 .16
Cognitive function domain
Memory
Delayed word recall 415 0.12 0.01 0.23 .03 415 0.09 20.01 0.19 .09 415 0.05 20.05 0.14 .36
Logical Memory Test part A 395 0.08 20.04 0.19 .18 395 0.14 0.04 0.25 .01 395 0.10 0.0002 0.21 .05
Logical Memory Test part B 385 0.04 20.08 0.16 .53 385 0.15 0.04 0.25 .01 385 0.06 20.04 0.17 0.23
Incidental learning 378 0.23 0.11 0.35 .0002 378 0.24 0.12 0.35 ,.0001 378 0.19 0.08 0.30 .001
Language
Animal naming 425 0.09 20.01 0.20 .09 425 0.02 20.08 0.12 .70 425 0.01 20.08 0.11 .82
Boston Naming Test 407 0.07 20.02 0.16 .14 407 0.05 20.03 0.14 .20 407 0.02 20.06 0.10 .63
Word fluency 407 0.09 20.02 0.20 .10 407 0.02 20.08 0.12 .66 407 0.03 20.06 0.13 .49
Visuospatial
Clock time perception 405 0.10 20.02 0.22 .10 405 0.07 20.04 0.18 .22 405 0.05 20.06 0.16 .39
Attention
Trail making test part A 379 0.07 20.03 0.18 .16 379 0.01 20.09 0.10 .89 379 0.02 20.08 0.11 .74
Digit span backward 402 0.02 20.09 0.13 .75 402 0.12 0.01 0.22 .03 402 0.06 20.04 0.16 .24
Executive function
Digit symbol substitution 389 0.11 0.01 0.21 .03 389 20.005 20.10 0.09 .92 389 0.0001 20.09 0.09 .99
Trail making test part B 321 0.08 20.05 0.20 .25 321 0.11 20.01 0.22 .08 321 0.07 20.05 0.18 .24
PC aa C40:1 PC aa C40:2 PC aa C40:6
Neuropsychological tests n by 95% CI
P
value n b* 95% CI
P
value n b* 95% CI
P
value
Mini-mental state examination 388 0.01 20.11 0.13 .85 388 20.06 20.16 0.03 .18 388 0.10 0.01 0.19 .04
Cognitive function domain
Memory
Delayed word recall 415 0.11 20.02 0.24 .10 415 0.08 20.03 0.18 .15 415 0.08 20.02 0.18 .11
Logical Memory Test part A 395 0.09 20.04 0.23 .18 395 0.04 20.07 0.15 .49 395 0.11 0.01 0.22 .03
Logical Memory Test part B 385 0.05 20.09 0.18 .51 385 0.05 20.06 0.16 .37 385 0.09 20.02 0.20 .10
Incidental learning 378 0.12 20.03 0.27 .11 378 0.12 0.01 0.23 .04 378 0.20 0.08 0.31 .001
Language
Animal naming 425 0.01 20.12 0.13 .91 425 0.004 20.10 0.11 .93 425 0.03 20.06 0.13 .49
Boston Naming Test 407 20.03 20.13 0.08 .59 407 20.03 20.12 0.05 .43 407 0.04 20.04 0.12 .36
Word fluency 407 20.02 20.15 0.11 .77 407 0.04 20.07 0.14 .50 407 0.03 20.07 0.13 .51
Visuospatial
Clock time perception 405 0.06 20.09 0.20 .44 405 20.03 20.15 0.08 .55 405 0.06 20.04 0.17 .24
Attention
Trail making test part A 379 20.03 20.14 0.09 .67 379 0.02 20.08 0.11 .76 379 0.02 20.07 0.12 .62
Digit span backward 402 0.07 20.06 0.20 .28 402 0.08 20.03 0.18 .15 402 0.05 20.05 0.15 .31
Executive function
Digit symbol substitution 389 0.001 20.12 0.12 .98 389 20.02 20.11 0.08 .72 389 20.01 20.10 0.09 .88
Trail making test part B 321 0.03 20.12 0.18 .66 321 20.04 20.16 0.08 .49 321 0.06 20.05 0.18 .28
PC ae C40:6 Lyso PC a C18:2 Propionyl-L-carnitine (C3)
Neuropsychological tests n b* 95% CI
P
value n b* 95% CI
P
value n b* 95% CI
P
value
Mini-mental state examination 388 0.05 20.04 0.15 .29 388 20.10 20.19 20.01 .03 388 0.05 20.04 0.13 .29
Cognitive function domain
Memory
Delayed word recall 415 0.06 20.04 0.16 .27 415 0.01 20.08 0.11 .77 414 0.03 20.07 0.12 .59
Logical Memory Test part A 395 0.12 0.01 0.23 .04 395 20.09 20.19 0.02 .10 394 0.04 20.07 0.14 .50
Logical Memory Test part B 385 0.11 0.003 0.23 .04 385 20.03 20.14 0.07 .55 384 0.04 20.06 0.15 .44
Incidental learning 378 0.18 0.07 0.30 .002 378 20.02 20.13 0.08 .66 378 20.01 20.12 0.10 .86
Language
Animal naming 425 0.04 20.06 0.14 .42 425 20.10 20.19 20.01 .04 424 20.04 20.13 0.05 .42
Boston Naming Test 407 0.05 20.03 0.14 .24 407 20.03 20.11 0.05 .49 406 0.03 20.05 0.11 .42
(Continued )
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Table 4
The associations of selected phospholipids/metabolites with scores in the MMSE and 12 neuropsychological tests across the 441 participants in ARIC-NCS,
2011–2013 (Continued )
PC ae C40:6 Lyso PC a C18:2 Propionyl-L-carnitine (C3)
Neuropsychological tests n b* 95% CI
P
value n b* 95% CI
P
value n b* 95% CI
P
value
Word fluency 407 0.04 20.07 0.14 .50 407 0.01 20.08 0.11 .80 406 20.003 20.10 0.09 .95
Visuospatial
Clock time perception 405 0.05 20.06 0.16 .40 405 20.08 20.18 0.03 .16 404 0.004 20.10 0.11 .94
Attention
Trail making test part A 379 0.02 20.08 0.12 .69 379 20.01 20.10 0.08 .82 379 20.04 20.13 0.05 .35
Digit span backwards 402 0.13 0.03 0.24 .01 402 20.003 20.10 0.10 .95 401 20.01 20.11 0.09 .79
Executive function
Digit symbol substitution 389 0.02 20.07 0.12 .63 389 0.03 20.06 0.12 .51 389 20.09 20.18 20.003 .04
Trail making test part B 321 0.11 20.01 0.24 .06 321 20.01 20.13 0.10 .84 321 20.06 20.18 0.05 .28
NOTE. Linear regression adjusted for age, race, sex, APOE, body mass index, diabetes mellitus, drinking status, educational level, HDL cholesterol, smoking
status, sports index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, and prevalent coronary heart disease, heart
failure, or stroke at baseline.
*b per 1-SD change in the log(phospholipid).
yb for phospholipid as a three-group ordinal variable (below LOD, LOD2 , Median, Median).
D. Li et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 73-8280Although the same metabolomic method (i.e., the Bio-
Crate p180 kits) was used in our study and by Mapstone
et al. there were some key differences between the two
studies. First, the Mapstone study was longitudinal in na-
ture and was based on plasma samples collected from 124
cognitive normal individuals, 18 of who in 1–5 years (in
average of 2.1 years) developed aMCI/AD. However,
Mapstone et al. did report the ability of these 10 phospho-
lipids in discriminating aMCI/AD from cognitive normalTable 5
Linear regression of plasma phospholipids PC aa C38:0 and PC ae C40:6 and cogn
status
Neuropsychological tests
PC aa C38:0
n b* 95% CI
Mini-mental state examination 130 0.06 20.01 0.12
Cognitive function domain
Memory
Delayed word recall 153 0.07 20.05 0.18
Logical Memory Test part A 145 0.11 20.03 0.26
Logical Memory Test part B 145 0.16 20.001 0.32
Incidental learning 149 0.41 0.24 0.57
Language
Animal naming 153 0.14 0.01 0.28
Boston Naming Test 149 0.10 0.01 0.20
Word fluency 150 0.15 0.004 0.30
Visuospatial
Clock time perception 149 0.04 20.02 0.10
Attention
Trail making test part A 144 0.08 20.02 0.19
Digit span backward 149 0.19 0.05 0.34
Executive function
Digit symbol substitution 149 0.17 0.05 0.28
Trail making test part B 140 0.25 0.09 0.41
Linear regression adjusted for multiple covariates including age, race, sex, and A
HDL cholesterol, smoking status, sports index, systolic blood pressure, total chole
onary heart disease, heart failure, or stroke at baseline.
*b per 12SD change in the log(phospholipid).in a discovery set of 88 participants (35 aMCI/AD and
53 normal) and an independent validation of 41 partici-
pants (21 aMCI/AD and 20 normal). Our cross-sectional
study of 441 participants had a bigger sample size than
the Mapstone study (n 5 88 and 41 for discovery and in-
dependent validation sets, respectively). Second, our study
population was more heterogeneous, including 28%
African-American, where the Mapstone study included
only whites. In addition, our study population was lessitive scores of neuropsychological tests in older adults with normal cognitive
PC ae C40:6
P value n b* 95% CI P value
.095 130 0.04 20.03 0.11 .26
.24 153 0.07 20.05 0.20 .23
.13 145 0.14 20.01 0.29 .07
.05 145 0.19 0.02 0.35 .03
,.0001 149 0.33 0.15 0.51 .0004
.04 153 0.12 20.02 0.27 .09
.03 149 0.09 20.01 0.19 .07
.04 150 0.13 20.03 0.29 .10
.19 149 0.04 20.02 0.11 .18
.12 144 0.02 20.09 0.13 .70
.01 149 0.25 0.10 0.40 .002
.004 149 0.14 0.02 0.26 .03
.002 140 0.21 0.05 0.38 .01
POE, body mass index, diabetes mellitus, drinking status, educational level,
sterol, triglycerides, use of antihypertensive medications, and prevalent cor-
D. Li et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 73-82 81educated; Third, our study had expert adjudicated MCI
and dementia diagnoses as well as etiologies, where the
Mapstone study derived composite scores (standardized
z-scores) for each participant on cognitive tests and cate-
gorized the participants into aMCI/AD or cognitive
normal based on these composite scores. Fourth, the two
studies used different statistic methods: our study used a
multinomial logistic regression to assess the association
of the individual metabolites with the prevalence of
MCI and dementia; where the Mapstone study used
LASSO analysis to build linear classifier models [7]. Dif-
ferences in the statistical analyses could have a significant
impact on results. Last but not least, pre-analytical pro-
cess of blood samples is known to introduce variations
in metabolites including phospholipids. As indicated in
our study limitations, we used stored plasma samples,
and Mapstone used prospectively collected samples.
Although both studies collected plasma specimens
using standardized protocols to ensure high quality and
consistency within each study, differences in the sample
collection protocols should be emphasized. Beside these
key differences, plasma phospholipids may be affected
by environmental factors, such as diet and exercise, and
underlying mechanisms (e.g., inflammation and oxidative
stress) of many diseases such as hypertension and cardio-
vascular diseases [21–24]. To further add to the
complexity of the associations between plasma
phospholipids and cognition is the “dynamic” nature of
lipidomics, because the populations of lipids within a
cell membrane and within subcellular membranes
changes constantly, and single assessment obtains only a
snapshot picture of lipid profiles at the time of sample
extraction, stopping the lipid-modeling process [25].
The dynamic nature of lipidomics really emphasizes
the needs of validating biomarker studies with larger sam-
ple sizes, more heterogeneous study populations, and
quality of MCI and dementia diagnosis, like we did in
our study.
In conclusion, our study was unable to reproduce the
identities of many phospholipids found to be signifi-
cantly associated with prevalence of MCI and dementia
in other studies. However, we found significant associa-
tion of sphingomyelins with the prevalence of MCI and
dementia. Our results showed that, in general, some
phospholipids and metabolites were altered in MCI and
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1. Systematic review: Recent studies demonstrated that
plasma phospholipids and metabolites might predict
MCI and dementia [1–4]. However, these studies
were based on smaller sample sizes (i.e., 111–251
participants), included homogenous study populations
(mostly European Caucasian), and had variable
quality of mild cognitive impairment (MCI) and/or
dementia characterization.
2. Interpretation: By taking advantage of the rich
neurocognitive data collected as part of the ARIC
Neurocognitive Study (ARIC-NCS), we examined
cross-sectionally whether concentrations of phos-
pholipids/metabolites are associated with the
prevalence of MCI or dementia in a subset of 441
white and African-American participants. Our
findings suggested that although phospholipids
and metabolites were altered in MCI and dementia,
cross-sectional association was relatively weak
and prediction of MCI and dementia did not
improve on clinical variables.
3. Future directions: Applying other metabolomics
technologies on analysis of these specimens used in
this study, we may discover additional metabolites
that useful in the prediction of MCI and dementia.
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